Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VTYX
- Price
- 1.07
- Stock movement up
- +0.01 (0.94%)
- Company name
- Ventyx Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 75.66M
- Ent value
- 36.22M
- Price/Sales
- 70.32
- Price/Book
- 0.27
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -77.52%
- 3 year return
- -56.61%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-18
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VTYX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 70.32 |
| Price to Book | 0.27 |
| EV to Sales | 33.66 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 70.71M |
| EPS (TTM) | -2.16 |
| FCF per share (TTM) | -2.26 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.08M |
| Gross profit (TTM) | -51.00K |
| Operating income (TTM) | -164.18M |
| Net income (TTM) | -152.52M |
| EPS (TTM) | -2.16 |
| EPS (1y forward) | -2.13 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -4.74% |
| Operating margin (TTM) | -15258.18% |
| Profit margin (TTM) | -14175.09% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 61.77M |
| Net receivables | 0.00 |
| Total current assets | 289.41M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 301.10M |
| Accounts payable | 2.29M |
| Short/Current long term debt | 11.04M |
| Total current liabilities | 12.30M |
| Total liabilities | 22.33M |
| Shareholder's equity | 278.77M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -159.28M |
| Capital expenditures (TTM) | 446.00K |
| Free cash flow (TTM) | -159.72M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -54.71% |
| Return on Assets | -50.66% |
| Return on Invested Capital | -54.52% |
| Cash Return on Invested Capital | -57.09% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.06 |
| Daily high | 1.09 |
| Daily low | 1.03 |
| Daily Volume | 868K |
| All-time high | 46.65 |
| 1y analyst estimate | 11.14 |
| Beta | 0.37 |
| EPS (TTM) | -2.16 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 Jun 2025 |
Downside potential
Loading...
Downside potential data
| VTYX | S&P500 | |
| Current price drop from All-time high | -97.71% | -14.12% |
| Highest price drop | -98.21% | -56.47% |
| Date of highest drop | 7 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -54.50% | -11.07% |
| Avg time to new high | 44 days | 12 days |
| Max time to new high | 534 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
75.66M
Marketcap category
Small-cap
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Employees
75
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page